We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age–related macular degeneration: real world data from the Fight Retinal Blindness registry.
- Authors
Figueras-Roca, Marc; Parrado-Carrillo, Alba; Nguyen, Vuong; Casaroli-Marano, Ricardo P.; Moll-Udina, Aina; Gillies, Mark C.; Barthelmes, Daniel; Zarranz-Ventura, Javier
- Abstract
Purpose: To compare the outcomes of two different antivascular endothelial growth factor treatment regimens for treatment-naive eyes with neovascular age-related macular degeneration in routine clinical care at 12 and 24 months in Spain. Methods: Observational study using the Fight Retinal Blindness (FRB) outcomes registry platform. Eyes were treated with fixed bimonthly (FB) aflibercept group at one center and a treat-and-extend (TAE) regimen using either aflibercept or ranibizumab at the other center. Results: We included 192 eyes. Of these, 160 eyes (83%) completed 12 months (86 TAE and 74 FB) and 79 (41%) completed 24 months (46 for TAE and 33 for FB) of follow-up. No statistically significant differences (p > 0.05) were found regarding mean visual acuity (VA, logMAR letters) at baseline (12 month cohort TAE 59.6 vs FB 57.9; 24 month cohort TAE 61.7 vs FB 62.6), final mean VA (12 month cohort TAE 61.1 vs FB 63.0; 24 month cohort TAE 64.8 vs FB 66.4), and median number of injections (12 months TAE 7 vs FB 7; 24 months TAE 11 vs FB 12). However, the distribution of injection frequencies for the TAE group was larger, with 35% of TAE eyes receiving ≤ 6 injections at 12 months compared with only 19% of FB eyes (p = 0.024). Conclusion: Similar VA results were observed with TAE and FB regimens, with no differences in the median number of injections. However, the TAE approach seemed to deliver a wider distribution of injection frequencies due to its individualized approach, which may help reduce the burden of injections in some eyes.
- Subjects
SPAIN; MACULAR degeneration; ENDOTHELIAL growth factors; INJECTIONS; BLINDNESS; VISUAL acuity
- Publication
Graefe's Archive of Clinical & Experimental Ophthalmology, 2021, Vol 259, Issue 6, p1463
- ISSN
0721-832X
- Publication type
Article
- DOI
10.1007/s00417-020-05016-9